Insulet Q1 revenue rises 34%, beats estimates; lifts outlook

Insulet

06/05/2026 12:10

Overview

U.S. insulin pump maker's Q1 revenue rose 34%, beating analyst expectations

Adjusted EPS for Q1 beat analyst expectations

Company raised full-year revenue growth outlook after strong Q1 demand

Outlook

Insulet raises full-year total company revenue growth outlook to 21% - 23%

Company expects adjusted EPS growth above 25% for full-year 2026

Insulet sees FY 2026 adjusted operating margin expanding by about 100 bps year-over-year

Result Drivers

OMNIPOD GROWTH - Revenue growth driven by strong demand for Omnipod products, with total Omnipod revenue up 37% and international Omnipod revenue up 59% (45% in constant currency)

PRODUCT LAUNCHES & INNOVATION - Recent launches of Omnipod 5 and Omnipod Discover in new markets, and algorithm updates, contributed to growth and expanded market reach

OPERATING MARGIN EXPANSION - Company reported operating margin expansion, citing execution on strategic priorities and scaling global operations

Company press release: ID:nBwkqdcGa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$761.70 mln
$728.36 mln (21 Analysts)
Q1 Adjusted EPS
Beat
$1.42
$1.20 (21 Analysts)
Q1 EPS
$1.30
Q1 Net Income
Beat
$91.10 mln
$84.78 mln (17 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

Wall Street's median 12-month price target for Insulet Corp is $350.00, about 108.9% above its May 5 closing price of $167.53

The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 41 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)